Tanisha Carino is a health policy expert bringing over 20 years of experience driving growth and impact across multiple healthcare leadership positions in the government, private, and non-profit sectors. She most recently served as executive vice president, chief corporate affairs officer of Alexion, a Fortune 500 biotechnology company focused on rare disease, which was recently acquired by AstraZeneca. Prior to Alexion, she served as executive director of FasterCures, a Center of the Milken Institute, a nonpartisan think tank whose mission is working with global government, philanthropic, and business leaders to accelerate treatments to patients. Previously, Dr. Carino was an executive at GlaxoSmithKline where she led the United States policy function. She also spent over ten years with Avalere Health, a premiere strategic advisory services and business intelligence firm, and worked in the U.S. Medicare program to improve access for its beneficiaries and support the development of real-world evidence in the establishment of national coverage determinations. Dr. Carino is a Fulbright Fellow and earned her doctoral degree in health policy from Johns Hopkins University. She is associate faculty at the Johns Hopkins Bloomberg School of Public Health, and she serves as the Vice-Chair of the Board for the Alliance for Health Policy and on the Board of Directors of Silk Road Medical, a medical device innovator focused on the prevention of stroke. She is currently a Visiting Fellow and consultant at the White House Office of Science and Technology Policy.
In this recorded plenary session at the 2021 Annual Research Meeting, panelists discuss the ways in which, through evidence, data, experience and artificial intelligence, the very nature of evidence is changing.